NRD
PTGX icon

Nebula Research & Development’s Protagonist Therapeutics PTGX Stock Holding History

Nebula Research & Development’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-25,446
Closed -$736K – 1001
2024
Q1 		$736K Buy
25,446
+10,160
+66% +$276K 0.16% 227
2023
Q4 		$351K Buy
+15,286
New +$267K 0.11% 380

Other funds holding PTGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Nebula Research & Development's PTGX Position: Q2 2024 in Review

Nebula Research & Development sold out of Protagonist Therapeutics (PTGX) in Q2 2024, closing a stake of 25,446 shares — an estimated $736K sold.

Nebula Research & Development first reported a position in PTGX in Q4 2023 and held it in 2 quarters. The position peaked at $736K in Q1 2024. 188 funds tracked by Wall St. Rank hold PTGX as of Q2 2024.

  • Nebula Research & Development reported no remaining Protagonist Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Nebula Research & Development sold 25,446 Protagonist Therapeutics shares in Q2 2024, an estimated $736K.
  • Nebula Research & Development first reported a position in Protagonist Therapeutics in Q4 2023 and held it in 2 quarters.
  • Nebula Research & Development's Protagonist Therapeutics position peaked at $736K in Q1 2024.
  • 188 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2024.

Based on Nebula Research & Development's 13F filing for Q2 2024, filed 14 Aug 2024.